VALBENAZINE by Novartis is huntington’s disease is unclear, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (vmat2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
Drug data last refreshed 4h ago
Huntington’s disease is unclear, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Valbenazine in Obsessive Compulsive Disorder
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
Worked on VALBENAZINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.